Fotemustine-containing chemotherapy suggests lower toxicity with comparable efficacy versus high-dose methotrexate-based regimens: a retrospective cohort analysis.
코호트
1/5 보강
[BACKGROUND] Primary central nervous system lymphoma (PCNSL) is a rare but aggressive non-Hodgkin lymphoma.
- 95% CI 0.494-1.888
- HR 0.966
- 추적기간 28.5 months
- 연구 설계 cohort study
APA
Zhang X, Zhao W, et al. (2026). Fotemustine-containing chemotherapy suggests lower toxicity with comparable efficacy versus high-dose methotrexate-based regimens: a retrospective cohort analysis.. Therapeutic advances in medical oncology, 18, 17588359261426830. https://doi.org/10.1177/17588359261426830
MLA
Zhang X, et al.. "Fotemustine-containing chemotherapy suggests lower toxicity with comparable efficacy versus high-dose methotrexate-based regimens: a retrospective cohort analysis.." Therapeutic advances in medical oncology, vol. 18, 2026, pp. 17588359261426830.
PMID
41799703 ↗
Abstract 한글 요약
[BACKGROUND] Primary central nervous system lymphoma (PCNSL) is a rare but aggressive non-Hodgkin lymphoma. Currently, high-dose methotrexate (HD-MTX)-based chemotherapy remains the standard first-line treatment. Previous clinical trials have reported that fotemustine-containing regimens offer promising efficacy and tolerability as an alternative option.
[OBJECTIVES] To compare the efficacy, safety, and feasibility of fotemustine-containing regimens with HD-MTX-containing regimens for newly diagnosed PCNSL.
[DESIGN] A single-center, retrospective cohort study.
[METHODS] We retrospectively analyzed 114 newly diagnosed PCNSL patients treated between April 2011 and December 2021. Patients were classified into two cohorts: those receiving fotemustine-containing regimens ( = 72) and those receiving HD-MTX-containing regimens ( = 42). The primary efficacy endpoint was the objective response rate (ORR). Secondary endpoints included complete response rate, progression-free survival (PFS), and overall survival (OS). Adverse events (AEs) were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.
[RESULTS] No significant difference in ORR was observed between the fotemustine-containing group and HD-MTX-containing group (68% vs 67%, = 0.879). At a median follow-up of 28.5 months, the survival outcomes were comparable, with no statistically significant differences in either PFS (hazard ratio (HR) = 0.887, 95% confidence interval (CI): 0.522-1.508; = 0.654) or OS (HR = 0.966, 95% CI: 0.494-1.888; = 0.918). Notably, fotemustine-based therapy was associated with significantly fewer AEs, including leukopenia, thrombocytopenia, digestive tract toxicity, and mucositis (all < 0.05).
[CONCLUSION] Fotemustine-containing chemotherapeutics appear to confer a safer profile with comparable efficacy relative to HD-MTX-based regimens in newly-diagnosed PCNSL patients.
[OBJECTIVES] To compare the efficacy, safety, and feasibility of fotemustine-containing regimens with HD-MTX-containing regimens for newly diagnosed PCNSL.
[DESIGN] A single-center, retrospective cohort study.
[METHODS] We retrospectively analyzed 114 newly diagnosed PCNSL patients treated between April 2011 and December 2021. Patients were classified into two cohorts: those receiving fotemustine-containing regimens ( = 72) and those receiving HD-MTX-containing regimens ( = 42). The primary efficacy endpoint was the objective response rate (ORR). Secondary endpoints included complete response rate, progression-free survival (PFS), and overall survival (OS). Adverse events (AEs) were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.
[RESULTS] No significant difference in ORR was observed between the fotemustine-containing group and HD-MTX-containing group (68% vs 67%, = 0.879). At a median follow-up of 28.5 months, the survival outcomes were comparable, with no statistically significant differences in either PFS (hazard ratio (HR) = 0.887, 95% confidence interval (CI): 0.522-1.508; = 0.654) or OS (HR = 0.966, 95% CI: 0.494-1.888; = 0.918). Notably, fotemustine-based therapy was associated with significantly fewer AEs, including leukopenia, thrombocytopenia, digestive tract toxicity, and mucositis (all < 0.05).
[CONCLUSION] Fotemustine-containing chemotherapeutics appear to confer a safer profile with comparable efficacy relative to HD-MTX-based regimens in newly-diagnosed PCNSL patients.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Effects of varicocele and microsurgical varicocelectomy on the metabolites in semen.
- Novel staurosporine-type indolocarbazole glycoalkaloids as potent and selective FLT3-ITD inhibitors for acute myeloid leukemia.
- IDH1 mutation creates a dependency on fatty acid metabolism that underlies sensitivity to cuproptosis in acute myeloid leukemia cells.
- MASH and liver fibrosis: Clinical trials to watch.
- E3 ubiquitin ligase DTX3L promotes breast cancer progression by enhancing PKCα ubiquitination and inhibiting the p38 MAPK signaling pathway.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Efficacy of first-line immunochemotherapy across KRAS mutation subtypes in advanced lung adenocarcinoma.
- Primary Malignant Melanoma of the Lung With a Long-Term Course: A Case Report.
- Mantle Cell Lymphoma with Persistent Massive Pleural Effusions Requiring Invasive Mechanical Ventilation and Bilateral Continuous Thoracic Drainage.
- Cooling immunochemotherapy and hematopoietic stem cell transplantation for refractory systemic epstein-barr virus-positive T-cell lymphoma in children: a single institution experience.
- Real-World Outcomes of First-Line Immune-Based Combination Therapies in Bone-Metastatic Clear Cell Renal Cell Carcinoma.
- Gastric and upper gastrointestinal oncology: integrating breakthroughs from prevention to precision therapeutics.